03.09.21 -- Incorporating Excipients Into QbD Studies For Drug Development -- An Introduction
03.09.21 -- Incorporating Excipients Into QbD Studies For Drug Development -- An Introduction Orphan drugs are notorious for their high costs and risk factors, which are attributed to smaller patient pools and higher development and launch costs. Attend this webinar to learn more about key trends that are causing the rise of orphan drug indications, fast-tracking early development phases that will lead to commercial success, and more! By Brian Carlin (DFE Pharma), Chris Moreton (FinnBrit Consulting), Dave Schoneker (Black Diamond Consulting), K...
Source: pharmaceuticalonline.com